Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience

• Published in: OncoTargets and therapy Vol. 12; pp. 3077 - 3085
• Main Authors: Cavanna, Luigi, Stroppa, Elisa Maria, Citterio, Chiara, Mordenti, Patrizia, Di Nunzio, Camilla, Peveri, Silvia, Orlandi, Elena, Vecchia, Stefano
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-04-2019; Taylor & Francis Ltd; Dove
• Subjects: 5-Fluorouracil; Adenocarcinoma; Anemia; Cancer metastasis; Care and treatment; Chemotherapy; Comparative analysis; Folinic acid; Medical prognosis; Metastasis; Neutropenia; Oncology; Operating systems (Software); Original Research; Pancreatic cancer; Pegfilgrastim; Toxicity; locally advanced pancreatic cancer; FOLFIRINOX; chemotherapy; metastatic pancreatic cancer
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S200754

Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) significantly increases survival in advanced pancreatic cancer, compared to employing only gemcitabine (GEM), toxicities have tempered enthusiasm for its use.
This study retrospectively analyses the real-world clinical practice with full and attenuated doses of FOLFIRINOX in unselected patients with locally advanced unresectable or metastatic pancreatic cancer, treated at an Italian general hospital. Efficacy, tolerability, and toxicity were evaluated, and overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier method.
Fifty consecutive patients with advanced (13) or metastatic (37) pancreatic adenocarcinomas were treated with FOLFIRINOX at the Medical Oncology Unit, Piacenza General Hospital, North Italy. The first enrolled consecutive 18 patients (36%) of this series started the treatment with a full dose of the regimen, while the subsequent 32 (64%) consecutive patients received dose attenuation (-20% bolus fluorouracil and -25% irinotecan). In the entire group, the response rate, median OS, and median PFS were 30%, 10.1 months, and 5.6 months, respectively, with no differences in objective response in the 32 patients that received an attenuated dose compared with the 18 patients receiving a full dose of chemotherapy. However, neutropenia, anemia, fatigue, and vomiting were statistically increased in the 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose of FOLFIRINOX (
<0.05).
This study demonstrates the efficacy and tolerability of modified FOLFIRINOX in advanced and metastatic pancreatic cancer.